UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8
UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.
Stocks · News reference
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 3.33 percent increase over losses of $(0.60) per share from the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.
Filed: 2026-10-02 AccNo: 0001193125-26-412300 Size: 169 KB Item 8.01: Other Events